Insider Buying: Viridian Therapeutics, Inc. (NASDAQ:VRDN) COO Buys 5,000 Shares of Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) COO Thomas W. Beetham acquired 5,000 shares of the stock in a transaction on Friday, September 27th. The shares were acquired at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares of the company’s stock, valued at approximately $140,460. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN opened at $23.61 on Wednesday. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $1.51 billion, a PE ratio of -5.25 and a beta of 1.03. Viridian Therapeutics, Inc. has a twelve month low of $10.93 and a twelve month high of $24.59. The company has a 50-day moving average price of $17.31 and a two-hundred day moving average price of $15.28.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. Equities analysts forecast that Viridian Therapeutics, Inc. will post -3.94 EPS for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VRDN. Quest Partners LLC boosted its position in Viridian Therapeutics by 344.0% during the second quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after purchasing an additional 4,692 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of Viridian Therapeutics by 19.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after acquiring an additional 799 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Viridian Therapeutics by 24.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after acquiring an additional 2,359 shares during the period. AlphaCentric Advisors LLC boosted its position in shares of Viridian Therapeutics by 108.3% in the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock valued at $163,000 after acquiring an additional 6,500 shares during the period. Finally, Arizona State Retirement System boosted its position in shares of Viridian Therapeutics by 14.7% in the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after acquiring an additional 1,688 shares during the period.

Wall Street Analyst Weigh In

Several analysts have recently commented on VRDN shares. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Viridian Therapeutics in a report on Tuesday, September 10th. Oppenheimer reiterated an “outperform” rating and issued a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Needham & Company LLC increased their price target on shares of Viridian Therapeutics from $30.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. The Goldman Sachs Group increased their price target on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. Finally, Wedbush restated an “outperform” rating and set a $42.00 price target on shares of Viridian Therapeutics in a research report on Monday, July 29th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $35.80.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.